Home › Companies › SAREPTA THERAPEUTICS INC. › 2023-2024

SAREPTA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and SAREPTA THERAPEUTICS INC.’s Form 8-K, filed 2024-06-07 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
427Asset managers
3,113Fund votes
2024-06-06Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore SAREPTA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SAREPTA THERAPEUTICS INC.

These tallies are SAREPTA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SAREPTA THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-06
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Douglas S. Ingram	71,684,003	1,141,805	16,569	--	8,161,580	Majority: yes
Elect Director: Hans Wigzell, M.D., Ph.D.	62,357,683	10,424,422	60,272	--	8,161,580	Majority: yes
Elect Director: Kathryn J. Boor, Ph.D.	66,169,655	6,656,367	16,355	--	8,161,580	Majority: yes
Elect Director: Michael Chambers	71,087,155	1,737,715	17,507	--	8,161,580	Majority: yes
Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2023	63,631,197	9,004,619	206,561	--	8,161,580	Majority: yes
Proposal 3: Ratification of KPMG as the Company's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ended December 31, 2024	77,132,548	3,758,836	112,573	--	--	Majority: yes

Source: SAREPTA THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-07 — read the filing on EDGAR.

How asset managers voted at the SAREPTA THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 427 asset managers that disclosed a SAREPTA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of SAREPTA THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. advisory vote to approve, on a non-binding basis, named executive officer compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 20 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 63,631,197AGAINST: 9,004,619

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2023”): 63,631,197 for, 9,004,619 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,490,157 outstanding shares: 67% for, 10% against (77% of the company cast a for/against vote).

The 422 asset managers below cast 94% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 93%

FOR: 93.4%AGAINST: 6.4%ABSTAIN: 0.2%NOT VOTED: 0.0%UNKNOWN: 0.0%

Largest asset managers voting on “advisory vote to approve, on a non-binding basis, named executive officer compensation” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
OAK RIDGE INVESTMENTS LLC	17,000,000	0	For
Vanguard	10,856,862	0	For
Capital Group	8,038,446	0	For
BlackRock	5,257,037	1,064	For
Janus Henderson	4,781,447	0	For
Fidelity	4,376,600	0	For
T. Rowe Price	3,831,107	0	For
Avoro Capital Advisors LLC	3,487,894	0	For
Wellington	3,137,872	0	For
JANUS INVESTMENT FUND	2,936,541	0	For
State Street	2,561,803	0	For
FARALLON CAPITAL MANAGEMENT LLC	0	2,437,500	Against
JPMorgan	2,337,110	0	For
EcoR1 Capital, LLC	1,919,835	0	For
AMCAP FUND	1,540,079	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,519,615	0	For
BNY Mellon	1,431,797	0	For
Federated Hermes	1,218,363	0	For
Thrivent	1,204,192	0	For
Charles Schwab	1,177,273	0	For
Newton Investment Management North America, LLC	1,033,151	0	For
PICTET ASSET MANAGEMENT SA	928,537	0	For
ORBIMED ADVISORS LLC	0	610,500	Against
Camber Capital Management LP	585,000	0	For
Nuveen	564,724	0	For

Showing the 25 largest of 422 asset managers. See all 422 in the interactive database.

2. ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2024

AUDIT-RELATEDMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 77,132,548AGAINST: 3,758,836

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Ratification of KPMG as the Company's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the”): 77,132,548 for, 3,758,836 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,490,157 outstanding shares: 82% for, 4% against (86% of the company cast a for/against vote).

The 118 asset managers below cast 99.3% of the shares they voted on this item FOR (34,136,747 for, 225,265 against).

FOR 99.3%

FOR: 34,136,747 (99.3%)AGAINST: 225,265 (0.7%)ABSTAIN: 2,144 (0.0%)

Largest asset managers voting on “ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the curren” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	10,724,218	0	For
Capital Group	3,220,374	0	For
Fidelity	3,027,757	0	For
JANUS INVESTMENT FUND	2,936,541	0	For
BlackRock	2,487,598	0	For
AMCAP FUND	1,540,079	0	For
T. Rowe Price	1,404,446	0	For
BNY Mellon	784,664	0	For
JPMorgan	712,675	0	For
State Street	648,003	2,520	For
Federated Hermes	609,175	0	For
Thrivent	597,457	0	For
Charles Schwab	587,119	0	For
Hartford	549,206	0	For
TIAA	514,069	0	For
Jackson National	322,257	0	For
Aberdeen	191,857	0	For
Voya	165,265	0	For
Allspring	162,820	0	For
CARILLON SERIES TRUST	155,326	0	For
Equitable	147,874	0	For
Columbia Threadneedle	147,737	0	For
Dimensional	140,107	0	For
MUTUAL FUND SERIES TRUST	135,730	0	For
AIG/SunAmerica	121,148	0	For

Showing the 25 largest of 118 asset managers. See all 118 in the interactive database.

3. to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Hans Wigzell, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST 14%

FOR: 62,357,683AGAINST: 10,424,422

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Hans Wigzell, M.D., Ph.D.”): 62,357,683 for, 10,424,422 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,490,157 outstanding shares: 66% for, 11% against (77% of the company cast a for/against vote).

The 116 asset managers below cast 91% of the shares they voted on this item FOR (31,093,255 for, 3,169,626 against).

FOR 91%9%

FOR: 31,093,255 (90.7%)AGAINST: 3,169,626 (9.2%)ABSTAIN: 3,543 (0.0%)

Largest asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	10,724,218	0	For
Capital Group	3,220,374	0	For
Fidelity	3,020,435	7,322	For
JANUS INVESTMENT FUND	2,936,541	0	For
BlackRock	2,487,598	0	For
AMCAP FUND	1,540,079	0	For
T. Rowe Price	0	1,404,446	Against
BNY Mellon	784,664	0	For
JPMorgan	712,675	0	For
State Street	13,036	637,487	Against
Federated Hermes	609,175	0	For
Thrivent	597,457	0	For
Charles Schwab	587,119	0	For
Hartford	549,206	0	For
TIAA	514,069	0	For
Jackson National	162,613	159,644	For
Aberdeen	191,857	0	For
Voya	165,265	0	For
Allspring	162,820	0	For
CARILLON SERIES TRUST	155,326	0	For
Equitable	82,185	65,689	For
Columbia Threadneedle	0	147,737	Against
Dimensional	140,107	0	For
MUTUAL FUND SERIES TRUST	135,730	0	For
AIG/SunAmerica	121,148	0	For

Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.

4. to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Kathryn J. Boor, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 66,169,655AGAINST: 6,656,367

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kathryn J. Boor, Ph.D.”): 66,169,655 for, 6,656,367 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,490,157 outstanding shares: 70% for, 7% against (77% of the company cast a for/against vote).

The 116 asset managers below cast 93% of the shares they voted on this item FOR (31,944,041 for, 2,318,840 against).

FOR 93%

FOR: 31,944,041 (93.2%)AGAINST: 2,318,840 (6.8%)ABSTAIN: 3,543 (0.0%)

Largest asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	10,724,218	0	For
Capital Group	3,220,374	0	For
Fidelity	3,020,435	7,322	For
JANUS INVESTMENT FUND	2,936,541	0	For
BlackRock	2,487,598	0	For
AMCAP FUND	1,540,079	0	For
T. Rowe Price	0	1,404,446	Against
BNY Mellon	784,664	0	For
JPMorgan	712,675	0	For
State Street	649,054	1,469	For
Federated Hermes	609,175	0	For
Thrivent	597,457	0	For
Charles Schwab	587,119	0	For
Hartford	549,206	0	For
TIAA	514,069	0	For
Jackson National	162,613	159,644	For
Aberdeen	191,857	0	For
Voya	165,265	0	For
Allspring	162,820	0	For
CARILLON SERIES TRUST	155,326	0	For
Equitable	82,185	65,689	For
Columbia Threadneedle	147,737	0	For
Dimensional	140,107	0	For
MUTUAL FUND SERIES TRUST	135,730	0	For
AIG/SunAmerica	121,148	0	For

Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.

5. to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Michael Chambers

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 71,087,155AGAINST: 1,737,715

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael Chambers”): 71,087,155 for, 1,737,715 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,490,157 outstanding shares: 75% for, 2% against (77% of the company cast a for/against vote).

The 116 asset managers below cast 98% of the shares they voted on this item FOR (33,700,757 for, 562,124 against).

FOR 98%

FOR: 33,700,757 (98.3%)AGAINST: 562,124 (1.6%)ABSTAIN: 3,543 (0.0%)

Largest asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	10,724,218	0	For
Capital Group	3,220,374	0	For
Fidelity	3,020,435	7,322	For
JANUS INVESTMENT FUND	2,936,541	0	For
BlackRock	2,487,598	0	For
AMCAP FUND	1,540,079	0	For
T. Rowe Price	1,064,377	340,069	For
BNY Mellon	784,664	0	For
JPMorgan	712,675	0	For
State Street	649,835	688	For
Federated Hermes	609,175	0	For
Thrivent	597,457	0	For
Charles Schwab	587,119	0	For
Hartford	549,206	0	For
TIAA	514,069	0	For
Jackson National	322,257	0	For
Aberdeen	191,857	0	For
Voya	165,265	0	For
Allspring	162,820	0	For
CARILLON SERIES TRUST	155,326	0	For
Equitable	82,185	65,689	For
Columbia Threadneedle	147,737	0	For
Dimensional	140,107	0	For
MUTUAL FUND SERIES TRUST	135,730	0	For
AIG/SunAmerica	121,148	0	For

Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.

6. to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Douglas S. Ingram

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 71,684,003AGAINST: 1,141,805

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Douglas S. Ingram”): 71,684,003 for, 1,141,805 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,490,157 outstanding shares: 76% for, 1% against (77% of the company cast a for/against vote).

The 116 asset managers below cast 99.9% of the shares they voted on this item FOR (34,261,918 for, 963 against).

FOR 99.9%

FOR: 34,261,918 (100.0%)AGAINST: 963 (0.0%)ABSTAIN: 3,543 (0.0%)

Largest asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	10,724,218	0	For
Capital Group	3,220,374	0	For
Fidelity	3,027,757	0	For
JANUS INVESTMENT FUND	2,936,541	0	For
BlackRock	2,487,598	0	For
AMCAP FUND	1,540,079	0	For
T. Rowe Price	1,404,446	0	For
BNY Mellon	784,664	0	For
JPMorgan	712,675	0	For
State Street	649,562	961	For
Federated Hermes	609,175	0	For
Thrivent	597,457	0	For
Charles Schwab	587,119	0	For
Hartford	549,206	0	For
TIAA	514,069	0	For
Jackson National	322,257	0	For
Aberdeen	191,857	0	For
Voya	165,265	0	For
Allspring	162,820	0	For
CARILLON SERIES TRUST	155,326	0	For
Equitable	147,874	0	For
Columbia Threadneedle	147,737	0	For
Dimensional	140,107	0	For
MUTUAL FUND SERIES TRUST	135,730	0	For
AIG/SunAmerica	121,148	0	For

Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.

7. Election of Directors (Majority Voting)

DIRECTOR ELECTIONS

All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%

Largest asset managers voting on “Election of Directors (Majority Voting)” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
Simplify Exchange Traded Funds	90,523	0	0	0	For
Ultimus Managers Trust	7,209	0	0	0	For

Largest SAREPTA THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of SAREPTA THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 94,490,157 shares outstanding at the time of that meeting.

Top SAREPTA THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	OAK RIDGE INVESTMENTS LLC	17.99%
2	Vanguard	11.49%
3	Capital Group	8.51%
4	BlackRock	5.56%
5	Janus Henderson	5.06%
6	Fidelity	4.63%
7	T. Rowe Price	4.05%
8	Avoro Capital Advisors LLC	3.69%
9	Wellington	3.32%
10	JANUS INVESTMENT FUND	3.11%

Reported SAREPTA THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

SAREPTA THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Shares Issued and Outstanding 3/31/2024	100.00%	DEF14A
BlackRock	13.97%	13F
Vanguard Group	11.45%	13F
Janus Henderson Group plc, 201 Bishopsgate, London, EC2M 3AE, United Kingdom	5.66%	DEF14A
Capital International Investors	5.02%	DEF14A
Wellington Management	3.44%	13F
Richard J. Barry	3.43%	DEF14A
Douglas Ingram	2.74%	DEF14A
Citadel Advisors	2.26%	13F
State Street	2.25%	13F

Percentages above are of 94,490,157 shares outstanding, as reported by SAREPTA THERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SAREPTA THERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At SAREPTA THERAPEUTICS INC.'s shareholder meeting held 2024-06-06, in the 2023-2024 proxy season, 427 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,113 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — advisory vote to approve, on a non-binding basis, named executive officer compensation — FOR was 88% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SAREPTA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-07.

SAREPTA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.